$1.044
+0.182 (+17.44%)At close
Technical Sentiment
Overall Consensus
Technical Analysis Consensus
Moving Average Consensus
Radiopharm Theranostics Ltd (RADX) Moving Averages Convergence Divergence (MACD) indicator is -0.15, suggesting RADX is Sell.
Radiopharm Theranostics Ltd (RADX) 20-Day simple moving average is 1.00, while Radiopharm Theranostics Ltd (RADX) share price is $—, making it Buy.
Radiopharm Theranostics Ltd (RADX) 60-Day simple moving average is 1.61, while Radiopharm Theranostics Ltd (RADX) share price is $—, making it Sell.
Technical Analysis for RADX
AI Technical RADXAs of 2026-11-07, the technical board for Radiopharm Theranostics Ltd (RADX) reads sell: 3 indicators are flashing buy, 6 are indicating sell, and 4 are neutral. Price at $1.04 sits below the 60-day and 200-day moving averages and above the 5-day, 10-day and 20-day.
Momentum readings: RSI stands at 39.214, MACD stands at -0.148 (Sell), Stochastic %K stands at 23.62, Stochastic %D stands at 18.611 and CCI stands at -37.261.
RADX trades below the 60-day SMA (1.61) and below the 200-day SMA (3.58). Immediate resistance sits at Classic R1 1.14, then R2 1.32. Support sits at Classic S1 0.80, then S2 0.64.
Radiopharm Theranostics Ltd (RADX) Support & Resistance Level
Radiopharm Theranostics Ltd (RADX) Technical Indicators
2026-11-07
| Name | Value |
|---|---|
| RSI_14 | 39.214 |
| STOCHk_14_3_3 | 23.620 |
| STOCHd_14_3_3 | 18.611 |
| CCI_20 | -37.261 |
| AO_5_34 | -0.233 |
| MOM_10 | -0.051 |
| MACD_12_26_9 | -0.148 |
Radiopharm Theranostics Ltd (RADX) Relative Strength Index (RSI_14) is 39.214, creating a Neutral signal.
Radiopharm Theranostics Ltd (RADX) Stochastic %K is 23.620, creating a Neutral signal.
Radiopharm Theranostics Ltd (RADX) Stochastic %D is 18.611, creating a Buy signal.
Radiopharm Theranostics Ltd (RADX) CCI_20 is -37.261, creating a Neutral signal.
Radiopharm Theranostics Ltd (RADX) Awesome Oscillator (AO) is -0.233, creating a Sell signal.
Radiopharm Theranostics Ltd (RADX) Momentum (MOM) is -0.051, creating a Sell signal.
Radiopharm Theranostics Ltd (RADX) Moving Average Convergence Divergence (MACD) is -0.148, creating a Sell signal.
Radiopharm Theranostics Ltd (RADX) Moving Average
2026-11-07
| Period | Simple | Signal |
|---|---|---|
| MA_5 | 0.920 | Buy |
| MA_10 | 0.964 | Buy |
| MA_20 | 1.004 | Buy |
| MA_60 | 1.606 | Sell |
| MA_200 | 3.578 | Sell |
| MA_250 | 3.856 | Sell |
Radiopharm Theranostics Ltd (RADX) 5-Day simple moving average is 0.920, while Radiopharm Theranostics Ltd (RADX) share price is $, making it a Buy.
Radiopharm Theranostics Ltd (RADX) 10-Day simple moving average is 0.964, while Radiopharm Theranostics Ltd (RADX) share price is $, making it a Buy.
Radiopharm Theranostics Ltd (RADX) 20-Day simple moving average is 1.004, while Radiopharm Theranostics Ltd (RADX) share price is $, making it a Buy.
Radiopharm Theranostics Ltd (RADX) 60-Day simple moving average is 1.606, while Radiopharm Theranostics Ltd (RADX) share price is $, making it a Sell.
Radiopharm Theranostics Ltd (RADX) 200-Day simple moving average is 3.578, while Radiopharm Theranostics Ltd (RADX) share price is $, making it a Sell.
Radiopharm Theranostics Ltd (RADX) 250-Day simple moving average is 3.856, while Radiopharm Theranostics Ltd (RADX) share price is $, making it a Sell.
Related articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.